EC Number   |
Application |
Reference |
|---|
   2.3.1.B43 | diagnostics |
elevated SIRT5 expression in human breast tumors correlates with poor patient prognosis |
758247 |
| 2.3.1.B43 | diagnostics |
SIRT5 is a promising biomarker for colorectal cancer |
777265 |
| 2.3.1.B43 | drug development |
SIRT5 is a drug target |
756522 |
| 2.3.1.B43 | drug development |
Sirt5 is a potential drug target for the treatment of cancer, Alzheimer's disease, and Parkinson's disease |
757350 |
| 2.3.1.B43 | medicine |
pharmacological interventions on SIRT5 expression may be useful in the treatment of oxidative stress-related cardiac injury |
729556 |
| 2.3.1.B43 | medicine |
SIRT5 is involved in influencing oocyte quality and in-vitro-fertilisation outcomes |
730922 |
| 2.3.1.B43 | medicine |
SIRT5 may have therapeutic value to treat hyperammonemia |
728932 |
| 2.3.1.B43 | medicine |
SIRT5 may serve as a potential prognostic factor and drug target for intervention in non-small cell lung cancer. SIRT5 is overexpressed in human non-small cell lung cancer cells, high expression of SIRT5 predicts poor survival. SIRT5 knockdown makes lung cancer cells more sensitive to drug (cis-diamminedichloroplatinum, 5-fluorouracil or bleomycin) treatment in vitro and in vivo. Nrf2, which is a core transcription factor for lung cancer growth and drug resistance, is a target of SIRT5 |
731010 |
| 2.3.1.B43 | medicine |
study provides a valuable target to improve of osteogenic differentiation of bone marrow mesenchymal stem cells (BM-MSCs) after many times of passages in vitro long-term passaged BM-MSCs exhibit upregulated SIRT5 expression, which leads to a decrease in UQCRC2 succinylation modification levels. This, in turn, enhances the activity of mitochondrial respiratory complex III and mitochondrial OXPHOS levels, impairs mitochondrial stability, and ultimately weakens the osteogenic differentiation capacity of BM-MSCs cells. Knockdown of SIRT5 can significantly reduce OXPHOS, maintain the normal function of mitochondria, and promote osteogenic differentiation of BM-MSCs even after many times of passages |
776985 |
| 2.3.1.B43 | pharmacology |
desuccinylation mediated by SIRT5 is an indispensable and synergistic requirement for histidine combination therapy against 6-mercaptopurine resistance, which is undisclosed previously and demonstrates a rational strategy to ameliorate chemoresistance and protect pediatric patients with B-cell lineage acute lymphoblastic leukemia (B-ALL) from disease progression or relapse |
776943 |
